Výsledky vyhledávání - "Suzanne Stack"

Figure S4 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Autor: Marc S. Ernstoff, Elizabeth A. Repasky, Hemn Mohammadpour, Igor Puzanov, Mark J. Bucsek, Joseph J. Drabick, Pauline Funchain, Suzanne Stack, Maria Levis, Carlos D. Cedeno, Paul K. Wallace, Joseph D. Tario, Cheryl Allen, Erik S. Knudsen, Agnieszka K. Witkiewicz, Wenyan Ji, Kristopher Attwood, Manu R. Pandey, Shipra Gandhi

Multispectral analysis of T-cell activation and exhaustion markers using antibodies for CD8, OX40, CTLA4, PD1, LAG3 and TIM3. A, Representative multiplex and monoplex images for a patient on the study using pre-treatment biopsy. B, Phenotyping was pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7cdb2e4243884866c51940aa4483d99
https://doi.org/10.1158/1078-0432.22479671.v1

Zobrazit plný text záznamu

Table S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

A. Absolute quantitative change in peripheral blood chemokines* from baseline to week 3 (week 3 minus baseline; change in mean value +/- standard deviation). B. Quantitative change in peripheral blood cellular fractions expressed as percentage of tot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a30168771bc4223b4904b7307bf3c19
https://doi.org/10.1158/1078-0432.22479662

Zobrazit plný text záznamu

Table S3 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Percentage of cells (m-MDSC, PMN-MDSC, T regulatory cells, T helper cells, cytotoxic T-cells, PD-L1+ melanoma cells, activated, partially exhausted and exhausted CD8+ T-cells) in archival tissue biopsies for 8/9 patients in the regions of interest se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3333b656ab50921443882088125c9141
https://doi.org/10.1158/1078-0432.22479656

Zobrazit plný text záznamu

Data from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Purpose:Increased β-adrenergic receptor (β-AR) signaling has been shown to promote the creation of an immunosuppressive tumor microenvironment (TME). Preclinical studies have shown that abrogation of this signaling pathway, particularly β2-AR, pro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0cf653fa4edd6225129efd7a070035
https://doi.org/10.1158/1078-0432.c.6530279

Zobrazit plný text záznamu

Figure S2 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Biomarker changes over time. A, Variations in chemokines IP-10, eotaxin and TNF-β in pg/ml. B, Variation in CD8+T-cells, m-MDSC, PMN-MDSC, regulatory T-cells (Tregs) expressed as percentage of total CD45+ cells, ratio of CD8+/ PMN-MDSC. C, Relative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41bba82a991ef68699acf3f7fb487225
https://doi.org/10.1158/1078-0432.22479677.v1

Zobrazit plný text záznamu

Table S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Adverse events by grade and frequency regardless of attribution

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94aa484af4457c0e3a823a68deaf17b5
https://doi.org/10.1158/1078-0432.22479665.v1

Zobrazit plný text záznamu

Figure S5 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

10x magnification of hematoxylin and eosin stained slides of archival tissue biopsies of patients at dose level 1, 2 and 3 on the study. Dose level 1 is propranolol 10 mg BID, dose level 2 is propranolol 20 mg BID, dose level 3 is propranolol 30 mg B

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cce24a441824b0707914c633fe2f8511
https://doi.org/10.1158/1078-0432.22479668.v1

Zobrazit plný text záznamu

Figure S1 from Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity

Perceived Stress scores (PSS). A, Waterfall plot showing best response per immune-modified RECIST as demonstrated by percentage (%) decrease in tumor size in the nine evaluable patients on the study reporting different PSS scores at baseline. B, Chan

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c66547851f89893c0833aa9b44ba76
https://doi.org/10.1158/1078-0432.22479680.v1

Zobrazit plný text záznamu

Coccidiomycosis in a dog

Autor: Mark, Rubensohn, Suzanne, Stack

Publikováno v: The Canadian veterinary journal = La revue veterinaire canadienne. 44(2)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::7bd4382f3e187d509768174d43c8afcb
https://pubmed.ncbi.nlm.nih.gov/12650050

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání